Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arun Gupta

Internal Medicine Manassas, VA Medical Doctor

NPI 1295756054 CMS profile 148900

9306 Forest Point Cir, Manassas, VA 20110

Open in the dashboard

General payments

$8,328

411 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arun Gupta of Manassas, VA is reported in the CMS Open Payments database as having received $8,328 across 411 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $886 38
2024 General $1,278 46
2023 General $1,041 45
2022 General $1,031 44
2021 General $1,278 74
2020 General $1,349 78
2019 General $1,465 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arun Gupta
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Arun Gupta were reported at $886. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Arun Gupta Internal Medicine median Middle half National median
2019 $1,465 $159 $48–$570 $163
2020 $1,349 $119 $33–$402 $114
2021 $1,278 $135 $37–$521 $132
2022 $1,031 $141 $42–$496 $149
2023 $1,041 $149 $45–$519 $160
2024 $1,278 $154 $47–$537 $164
2025 $886 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,071 48 payments
  2. Novo Nordisk Inc $915 51 payments
  3. Amgen Inc. $798 35 payments
  4. Pfizer Inc. $684 41 payments
  5. Sunovion Pharmaceuticals Inc. $502 31 payments
  6. AbbVie, Inc. $490 11 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $279 9 payments
  8. Janssen Pharmaceuticals, Inc $278 15 payments
  9. Sumitomo Pharma America, Inc. $233 10 payments
  10. Otsuka America Pharmaceutical, Inc. $205 10 payments
  11. Other $2,873 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,300 409 payments
  2. Education $28 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $708 44 payments
  2. FARXIGA $612 28 payments
  3. RYBELSUS $591 36 payments
  4. EVENITY $579 21 payments
  5. APTIOM $523 29 payments
  6. Prolia $335 19 payments
  7. ELIQUIS $281 19 payments
  8. Kerendia $279 9 payments
  9. UBRELVY $275 4 payments
  10. XARELTO $252 13 payments
  11. Other $6,099 320 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 220 drugs

Part D claims

16,299

Median for Internal Medicine: 777

Drug cost

$1,226,479

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 44 $187,153
Eliquis Apixaban Brand 346 $164,321
Xarelto Rivaroxaban Brand 206 $73,961
Ozempic Semaglutide Brand 55 $72,288
Tradjenta Linagliptin Brand 155 $55,420
Januvia Sitagliptin Phosphate Brand 100 $41,069
Breo Ellipta Fluticasone/Vilanterol Brand 79 $33,690
Rexulti Brexpiprazole Brand 15 $33,297
Trulicity Dulaglutide Brand 61 $24,401
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 22 $20,609

The 10 drugs with the highest cost, of 220 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$483,628

Of which drugs: $50,101

Medicare patients

984

Average age 79

Services billed

9,778

553 women, 431 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Chronic kidney disease 45%
Depression 39%
Diabetes 37%
Alzheimer's or dementia 36%
Ischemic heart disease 26%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 22 2,100 $43,241
Pcv20 vaccine im 90677 Office 18 18 $5,063
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 78 78 $1,708
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 62 $41

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $177
$177 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $141
$141 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $99
  • Lundbeck LLC $20
$119 15 —
QULIPTA
  • AbbVie, Inc. $114
$114 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $103
$103 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

411 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record